For instance, the identification of somatic alterations in genes such as epidermal growth factor receptor (EGFR), B-Raf proto-oncogene, serine/threonine kinase (BRAF), and mesenchymal epithelial transition (MET), as well as anaplastic lymphoma kinase (ALK), rearranged during transfection (RET) has transformed NSCLC diagnostic and therapeutic paradigms [4, 11]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.